A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational

Guglielmo Consales1, Elena Gramigni1, Lucia Zamidei2

  • 1Anaesthesia and Intensive Care Unit, Misericordia e Dolce Hospital, piazza dell'Ospedale 5, 59100 Prato, Italy.

Abstract

Insights

An Acinetobacter baumannii outbreak in an ICU was controlled with enhanced infection measures and tigecycline. Colistin was needed when resistance developed, highlighting the threat of pan-drug resistance.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Multidrug-resistant Acinetobacter baumannii (MRAB) poses a significant threat in intensive care units (ICUs).
  • Patient-to-patient transmission is a primary driver of MRAB outbreaks.
  • This study details an MRAB outbreak in a hospital ICU.

Purpose of the Study:

  • To describe and analyze an MRAB outbreak in an ICU setting.
  • To evaluate the effectiveness of infection control measures during the outbreak.
  • To assess antibiotic treatment strategies for MRAB infections.

Main Methods:

  • The study included MRAB-positive patients in a 2-room ICU.
  • Enhanced infection control protocols were implemented, including patient and environmental screening.
  • A 6-month follow-up was conducted to monitor for recurrence.

Main Results:

  • Four out of 26 patients were identified as MRAB positive, all located in one room.
  • No MRAB cases were detected in the second room or during follow-up.
  • Isolates were resistant to carbapenems but susceptible to tigecycline and colistin; tigecycline treatment was successful for two patients, with one developing resistance and requiring colistin.

Conclusions:

  • Enhanced infection control and appropriate antibiotic use successfully limited the MRAB outbreak.
  • Tigecycline facilitated rapid recovery, but subsequent resistance necessitates colistin.
  • The emergence of pan-drug resistance remains a critical concern in managing MRAB infections.

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...